Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17544594 | 0.91 | AGTR1 (0.33) | — | |
| SCHEMBL17544778 | 0.79 | TP53 (0.39) | KDM5ASMN1; SMN2 | |
| SCHEMBL17544555 | 0.78 | AGTR1 (0.39) | ALDH1A1CYP1A2CYP2C19TSHRSMN1; SMN2 | |
| SCHEMBL17549943 | 0.76 | EHMT2 (0.38) | SMN1; SMN2 | |
| SCHEMBL17544557 | 0.75 | BRD4 (0.33) | CNR2MC4RALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL17549921 | 0.74 | CASR (0.37) | TSHRSMN1; SMN2 | |
| SCHEMBL17544842 | 0.74 | CNR2 (0.33) | CNR2ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17549942 | 0.70 | TP53 (0.39) | KDM5ASMN1; SMN2 | |
| SCHEMBL17544743 | 0.70 | CNR2 (0.32) | CNR2MC4R | |
| SCHEMBL17549892 | 0.70 | AGTR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3186238-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| WO-2016033169-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | CNR2 4696/4885SCARB1 4193/4885MC4R 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.